Evidence map›Paper›PMID 31933254›Full record

ArticlePharmaceutical medicine2019

Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation.

Ruta Mockute, Sameen Desai, Sujan Perera, Bruno Assuncao, Karolina Danysz, Niki Tetarenko, Darpan Gaddam, Danielle Abatemarco, Mark Widdowson, Sheryl Beauchamp and 2 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Pharmaceutical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Fast Methods for Drug Approval: Research Perspectives for Pandemic Preparedness.International journal of environmental research and public health · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ruta MockuteCelgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA. Rmockute@celgene.com.ORCID http://orcid.org/0000-0002-0947-8014
Sameen DesaiCelgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.
Sujan PereraIBM Watson Health, Almaden Research Center, San Jose, CA, USA.
Bruno AssuncaoCelgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.
Karolina DanyszCelgene Corporation, Boudry, Switzerland.
Niki TetarenkoCelgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.
Darpan GaddamCelgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.
Danielle AbatemarcoCelgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.
Mark WiddowsonCelgene Corporation, Stockley Park, UK.
Sheryl BeauchampCelgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.
Salvatore CicirelloCelgene Corporation, Boudry, Switzerland.
Edward MingleCelgene Corporation, 86 Morris Avenue, Summit, NJ, 07901, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPharmacovigilance (PV) detects, assesses, and prevents adverse events (AEs) and other drug-related problems by collecting, evaluating, and acting upon AEs. The volume of individual case safety reports (ICSRs) increases yearly, but it is estimated that more than 90% of AEs go unreported. In this landscape, embracing assistive technologies at scale becomes necessary to obtain a higher yield of AEs, to maintain compliance, and transform the PV professional work life.

aimThe aim of this study was to identify areas across the PV value chain that can be augmented by cognitive service solutions using the methodologies of contextual analysis and cognitive load theory. It will also provide a framework of how to validate these PV cognitive services leveraging the acceptable quality limit approach.

methodsThe data used to train the cognitive service were an annotated corpus consisting of 20,000 ICSRS from which we developed a framework to identify and validate 40 cognitive services ranging from information extraction to complex decision making. This framework addresses the following shortcomings: (1) needing subject-matter expertise (SME) to match the artificial intelligence (AI) model predictions to the gold standard, commonly referred to as 'ground truth' in the AI space, (2) ground truth inconsistencies, (3) automated validation of prediction missing context, and (4) auto-labeling causing inaccurate test accuracy. The method consists of (1) conducting contextual analysis, (2) assessing human cognitive workload, (3) determining decision points for applying artificial intelligence (AI), (4) defining the scope of the data, or annotated corpus required for training and validation of the cognitive services, (5) identifying and standardizing PV knowledge elements, (6) developing cognitive services, and (7) reviewing and validating cognitive services.

resultsBy applying the framework, we (1) identified 51 decision points as candidates for AI use, (2) standardized the process to make PV knowledge explicit, (3) embedded SMEs in the process to preserve PV knowledge and context, (4) standardized acceptability by using established quality inspection principles, and (5) validated a total of 126 cognitive services.

conclusionThe value of using AI methodologies in PV is compelling; however, as PV is highly regulated, acceptability will require assurances of quality, consistency, and standardization. We are proposing a foundational framework that the industry can use to identify and validate services to better support the gathering of quality data and to better serve the PV professional.

Indexed as

Adverse Drug Reaction Reporting SystemsAlgorithmsArtificial IntelligenceCognitionDatabases, FactualDecision MakingDrug-Related Side Effects and Adverse ReactionsGuideline AdherenceHumansMachine LearningPatient SafetyPharmacovigilanceWorkload

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.